BridgeMD
New treatment option for Overweight
Official title A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
ClinicalTrials.gov ID: NCT07392190
What this study is testing
What is Eloralintide?
Eloralintide is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for overweight.
Also referred to as LY3841136.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Are on stable incretin therapy at screening
- With persistent obesity or overweight defined as:
- ≥30 kg/m2 OR
- ≥27 kg/m2 with at least one existing obesity related complication at screening:
- hypertension
You likely can't join if
- Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
- Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was...
- Have type 1 diabetes
- Have taken any of the following antihyperglycemic medications within 90 days before screening:
- dipeptidyl peptidase-4 (DPP-4) inhibitors
- amylin analogs
See the full eligibility criteria
- Are on stable incretin therapy at screening
- With persistent obesity or overweight defined as:
- ≥30 kg/m2 OR
- ≥27 kg/m2 with at least one existing obesity related complication at screening:
- hypertension
- dyslipidemia
- obstructive sleep apnea
- cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure), or
- type 2 diabetes
- Have a stable body weight (\<5% body weight change) at screening
- Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
- Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
- Have type 1 diabetes
- Have taken any of the following antihyperglycemic medications within 90 days before screening:
- dipeptidyl peptidase-4 (DPP-4) inhibitors
- amylin analogs
- insulin
- Have had within 90 days prior to screening:
- heart attack
- stroke
- coronary artery revascularization
- unstable angina, or
- hospitalization due to congestive heart failure
- Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
The study team makes the final eligibility decision.
Where it's taking place
- Birmingham, Alabama, United States
- Phoenix, Arizona, United States
- Scottsdale, Arizona, United States
- Tucson, Arizona, United States
- Irvine, California, United States
- La Jolla, California, United States
- La Mesa, California, United States
- Rolling Hills Estates, California, United States
- Sacramento, California, United States
- San Diego, California, United States
- Santa Ana, California, United States
- Tustin, California, United States
- Bridgeport, Connecticut, United States
- New Haven, Connecticut, United States
- Waterbury, Connecticut, United States
- Atlantis, Florida, United States
- Doral, Florida, United States
- Fleming Island, Florida, United States
- Jacksonville, Florida, United States
- Miami, Florida, United States
+ 132 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Birmingham, Alabama, United States; Phoenix, Arizona, United States; Scottsdale, Arizona, United States; Tucson, Arizona, United States; Irvine, California, United States; La Jolla, California, United States and 146 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.